| You
are here: Home: BCU 4|2003: J
Michael Dixon, MD, FRCS: Select publications
Select publications
Neoadjuvant endocrine therapy
Boeddinghaus I et al. Neoadjuvant Arimidex or tamoxifen, alone or combined,
for breast cancer
(IMPACT): PgR related reductions in proliferation marker KI67. Proc Am Soc
Clin Oncol 2000.
Abstract
360.
Cameron DA et al. Oestrogen receptor directed primary systemic therapy:
A randomised trial compared
with conventional therapy in operable breast cancer. Breast Cancer Res Treat
2002. Abstract
157.
Dixon JM et al. Anastrozole demonstrates clinical and biological effectiveness
in erbB2 ER-positive
breast cancers. Breast Cancer Res Treat 2002. Abstract
263.
Dixon JM et al. Neoadjuvant letrozole: The Edinburgh experience. Breast Cancer
Res Treat
2002;Abstract
264.
Dixon JM et al. Neoadjuvant endocrine therapy of breast cancer: A surgical
perspective. Eur J Cancer
2002;38(17):2214-21. Abstract
Dowsett M et al. HER-2 amplification impedes the antiproliferative
effects of hormone therapy in
estrogen receptor-positive primary breast cancer. Cancer Res 2001;61(23):8452-8.
Abstract
Ellis MJ et al. Letrozole (Femara®) is a more effective antiproliferative
agent than tamoxifen
irrespective of ErbB1 and/or ErbB2 positive status: Evidence from a phase III
randomized trial of
neoadjuvant endocrine therapy for postmenopausal women with estrogen receptor
positive primary
breast cancer. Breast Cancer Res Treat 2001. Abstract
10.
Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: Medical
perspectives. Clin Cancer Res
2001;7(12 Suppl):4388s-91s. Abstract
Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy
than tamoxifen for ErbB-1-
and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:
Evidence from a phase III
randomized trial. J Clin Oncol 2001;19(18):3808-16. Abstract
Ellis MJ. Preoperative endocrine therapy for older women with breast
cancer: Renewed interest in
an old idea. Cancer Control 2000;7(6):557-62. Abstract
Ingle JN. Current status of adjuvant endocrine therapy for breast cancer. Clin Cancer Res 2001 c;7(12
Suppl):4392s-6s. Abstract
Mauriac L et al. Neoadjuvant tamoxifen for hormone-sensitive non-metastatic
breast carcinomas in
early postmenopausal women. Ann Oncol 2002;13(2):293-8. Abstract
Miller WR et al. Changes in tumor proliferation following neoadjuvant
tamoxifen treatment may
predate response and predict for relapse. Breast Cancer Res Treat
2002. Abstract
231.
Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane
as neoadjuvant therapy. Cancer Control. 2002;9(2 Suppl):9-15. Abstract
Miller WR, Dixon JM. Antiaromatase agents: Preclinical data and
neoadjuvant therapy. Clin Breast
Cancer 2000;1 (Suppl 1):S9-S14. Abstract
Shannon C, Smith I. Is there still a role for neoadjuvant therapy
in breast cancer? Crit Rev Oncol
Hematol 2003;45(1):77-90. Abstract
|
